Sponsored Content
The following content is part of a paid sponsorship and is not an endorsement by the American Thoracic Society nor does it reflect the views or opinions of the American Thoracic Society.
-
Bronchiectasis Care with BRINSUPRI: The First Approval in NCFB
on
Read more: Bronchiectasis Care with BRINSUPRI: The First Approval in NCFBJoin us to learn about bronchiectasis management! Bronchiectasis expert Diego Maselli, MD, FCCP, ATSF, covers an overview of non-cystic fibrosis bronchiectasis (NCFB) and discusses an approach to treating the disease, with a focus on targeted management. Dr. Maselli is a paid speaker.
-
Visit the Sanofi & Regeneron Medical Booth at ATS 2026 to learn how
on
Read more: Visit the Sanofi & Regeneron Medical Booth at ATS 2026 to learn howVisit the Sanofi & Regeneron Medical Booth at ATS 2026 to learn how. Sanofi and Regeneron, working with Viz COPD™, are conducting a prospective multicenter study of AI in COPD care. This study aims to a novel approach to post-exacerbation COPD care by examining the ability of an AI-enabled Clinical Decision Support System (CDSS) to…
-
Bronchiectasis Care with BRINSUPRI: The First Approval in NCFB
on
Read more: Bronchiectasis Care with BRINSUPRI: The First Approval in NCFBJoin us to learn about bronchiectasis management! Bronchiectasis expert Diego Maselli, MD, FCCP, ATSF, covers an overview of non-cystic fibrosis bronchiectasis (NCFB) and discusses an approach to treating the disease, with a focus on targeted management. Dr. Maselli is a paid speaker.
-
A Collaborative Look at Clinical Data of Biologic Use in Appropriate Asthma and COPD Patients
on
Read more: A Collaborative Look at Clinical Data of Biologic Use in Appropriate Asthma and COPD PatientsIn this expert-led discussion, 2 clinical leaders sit down for a collaborative session on the use of DUPIXENT in patients with uncontrolled moderate-to-severe eosinophilic or OCS-dependent asthma and inadequately controlled chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. By targeting IL-4Ra, DUPIXENT inhibits two of the key drivers of type 2 inflammation, IL-4 and…
-
Explore Type 2 Inflammation in Asthma & COPD at ADVENT Booth #1301
on
Read more: Explore Type 2 Inflammation in Asthma & COPD at ADVENT Booth #1301At ATS 2026, the Sanofi & Regeneron ADVENT Medical Booth. Visit us to explore: Discover Your Clinical Persona, ADVENT Educational Resources & VR Experience. Engage with ADVENT resources, explore Type 2 inflammation across asthma and COPD, and discover personalized insights designed to enrich your learning experience.
-
Two Sessions. One Goal. Advancing Severe Asthma Care at ATS.
on
Read more: Two Sessions. One Goal. Advancing Severe Asthma Care at ATS.Severe asthma remains a complex disease shaped not only by airway inflammation, but by real‑world clinical, lifestyle, and patient factors that influence long‑term treatment decisions. At ATS 2026, join GSK Medical Affairs for two on‑site educational experiences that explore how evolving evidence and meaningful patient‑centered dialogue can inform more intentional severe asthma care.
-
A Discussion on JASCAYD® (nerandomilast) tablets
on
Read more: A Discussion on JASCAYD® (nerandomilast) tabletsPlease join expert physicians Dr. Mary Beth Scholand, University of Utah School of Medicine, and Dr. Mark Hamblin, University of Kansas Medical Center for an evening symposium where they will provide a comprehensive review of JASCAYD® (nerandomilast) tablets. During this event, Dr. Hamblin and Dr. Scholand will discuss the safety and efficacy data of JASCAYD…
-
Radiology Round-Up: The Importance of HRCT in Interstitial Lung Diseases
on
Read more: Radiology Round-Up: The Importance of HRCT in Interstitial Lung DiseasesPlease join expert thoracic radiologist Joseph Mammarappalil, MD, PhD of Duke University Medicine as he reviews the key role that radiologists play in the diagnosis and monitoring of interstitial lung disease (ILD) and interstitial lung abnormalities (ILAs). Dr. Mammarappallil will also walk through several cutting-edge resources aimed at expanding high resolution computed tomography (HRCT) knowledge…
-
An Overview of JASCAYD® (nerandomilast) tablets for the Clinician – An Interactive Learning Theater
on
Read more: An Overview of JASCAYD® (nerandomilast) tablets for the Clinician – An Interactive Learning TheaterPlease join expert physician Cedric Jamie Rutland, MD, as he explores the data and use of JASCAYD® (nerandomilast) tablets. During this learning theater program, Dr. Rutland will review the results of the clinical trial and discuss the use of JASCAYD in appropriate patients.
-
A Discussion on JASCAYD® (nerandomilast) tablets
on
Read more: A Discussion on JASCAYD® (nerandomilast) tabletsPlease join expert physicians Dr. Mary Beth Scholand, University of Utah School of Medicine, and Dr. Mark Hamblin, University of Kansas Medical Center for an evening symposium where they will provide a comprehensive review of JASCAYD® (nerandomilast) tablets. During this event, Dr. Hamblin and Dr. Scholand will discuss the safety and efficacy data of JASCAYD…
-
Join our expert panel as we discuss the importance of small airways in asthma management
on
Read more: Join our expert panel as we discuss the importance of small airways in asthma managementOn May 18th at 1:00 p.m., our expert panel, including Dr. Omar Usmani, Dr. Nicola Hanania, and Dr. Wanda Phipatanakul, will unravel small airway disease (SAD) detection and management in the everyday clinic for patients with asthma, and explore its prevalence, assessment, clinical significance, and treatment considerations.
-
Don’t miss the upcoming Innovation Theater sponsored by Savara
on
Read more: Don’t miss the upcoming Innovation Theater sponsored by SavaraJoin Dr. Kevin Davidson, MD, FCCP for an update on autoimmune pulmonary alveolar proteinosis (aPAP), covering pathophysiology, clinical presentation, diagnosis, and management. Following the presentation, Dr. Jeff Sippel, MD, will moderate a discussion blending clinical insights with the lived experience of Kelsea, a patient advocate living with aPAP.
-
How can AI be used in COPD care? Visit Sanofi and Regeneron at Booth #1301 to find out
on
Read more: How can AI be used in COPD care? Visit Sanofi and Regeneron at Booth #1301 to find outSanofi and Regeneron, working with Viz COPD™, are conducting a prospective multicenter study of AI in COPD care. This study aims to validate a novel approach to post-exacerbation COPD care by examining the ability of an AI-enabled System to improve pulmonologist follow-up and outcomes. The results of this study will inform clinical practice and may…
-
Gain practical insights into improving refractory chronic cough diagnosis and recognition by identifying clinical features of neuronal hypersensitivity.
on
Read more: Gain practical insights into improving refractory chronic cough diagnosis and recognition by identifying clinical features of neuronal hypersensitivity.Come join GSK Medical to learn more about a mechanism behind RCC, as well as guideline-based steps to diagnosing and recognizing RCC in the clinic.
-
Radiology Round-Up: The Importance of HRCT in Interstitial Lung Diseases
on
Read more: Radiology Round-Up: The Importance of HRCT in Interstitial Lung DiseasesPlease join expert thoracic radiologist Joseph Mammarappalil, MD, PhD of Duke University Medicine as he reviews the key role that radiologists play in the diagnosis and monitoring of interstitial lung disease (ILD) and interstitial lung abnormalities (ILAs). Dr. Mammarappallil will also walk through several cutting-edge resources aimed at expanding high resolution computed tomography (HRCT) knowledge…
-
Bronchiectasis Care with BRINSUPRI: The First Approval in NCFB
on
Read more: Bronchiectasis Care with BRINSUPRI: The First Approval in NCFBJoin us to learn about bronchiectasis management! Bronchiectasis expert Diego Maselli, MD, FCCP, ATSF, covers an overview of non-cystic fibrosis bronchiectasis (NCFB) and discusses an approach to treating the disease, with a focus on targeted management. This event takes place at Innovation Theater 6 on Tuesday, May 19, at 11:30 am ET. Dr. Maselli is…
-
Explore Type 2 Inflammation Across Asthma & COPD at ADVENT Booth #1301
on
Read more: Explore Type 2 Inflammation Across Asthma & COPD at ADVENT Booth #1301At ATS 2026, the Sanofi & Regeneron ADVENT Booth brings together interactive experiences and educational resources to explore Type 2 inflammation as a key feature underlying both asthma and COPD. Experience how it’s all connected: Discover Your Clinical Persona and Immersive VR Experience
-
Register now for 3 expert-led CME programs at ATS 2026—join in Orlando or stream live
on
Read more: Register now for 3 expert-led CME programs at ATS 2026—join in Orlando or stream liveMake the most of ATS 2026 with three expert-led CME programs designed to bring you the latest insights in respiratory and inflammatory disease management. Attend in person or join virtually from anywhere!
-
An Overview of JASCAYD® (nerandomilast) tablets for the Clinician – An Interactive Learning Theater
on
Read more: An Overview of JASCAYD® (nerandomilast) tablets for the Clinician – An Interactive Learning TheaterPlease join expert physician Cedric Jamie Rutland, MD, as he explores the data and use of JASCAYD® (nerandomilast) tablets. During this learning theater program, Dr. Rutland will review the results of the clinical trial and discuss the use of JASCAYD in appropriate patients.
-
A Discussion on JASCAYD® (nerandomilast) tablets
on
Read more: A Discussion on JASCAYD® (nerandomilast) tabletsPlease join expert physicians Dr. Mary Beth Scholand, University of Utah School of Medicine, and Dr. Mark Hamblin, University of Kansas Medical Center for an evening symposium where they will provide a comprehensive review of JASCAYD® (nerandomilast) tablets. During this event, Dr. Hamblin and Dr. Scholand will discuss the safety and efficacy data of JASCAYD…